Estradiol, tamoxifen and ICI 182,780 alter α3 and β1 integrin expression and laminin-1 adhesion in oral squamous cell carcinoma cell cultures

Oral Oncology

Volumn 44, Issue 1, 2008, Pages 94-99

  Nelson, Katja ^a   Helmstaedter, Victor ^b   Moreau, Cynthia ^b   Lage, Hermann ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

3 Integrin; 1 Integrin; Estrogen receptor

Indexed keywords

ALPHA3 INTEGRIN; BETA1 INTEGRIN; CELL ADHESION MOLECULE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; LAMININ 1; TAMOXIFEN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, CD29; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INTEGRIN ALPHA3; LAMININ; MEMBRANE PROTEINS; MOUTH NEOPLASMS; TAMOXIFEN;

EID: 37049020899     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.01.007     Document Type: Article

References (38)

1. Sturgis E.M., Wei Q., and Spitz M.R. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 31 (2004) 726-733
2. Janes S.M., and Watt F.M. New roles for integrins in squamous-cell carcinoma. Nat Rev Cancer 6 (2006) 175-183
3. Jin H., and Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 90 (2004) 561-565
4. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
5. Gilcrease M.Z. Integrin signaling in epithelial cells. Cancer Lett 247 (2007) 1-25
6. Ghosh S., Johnson J.J., Sen R., Mukhopadhyay S., Liu Y., Zhang F., et al. Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem 281 (2006) 13021-13029
7. Kramer R.H., Shen X., and Zhou H. Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev 24 (2005) 35-45
8. Giannelli G., Astigiano S., Antonaci S., Morini M., Barbieri O., Noonan D.M., et al. Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clin Exp Metastasis 19 (2002) 217-223
9. Owens D.M., and Watt F.M. Influence of beta1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: alpha3beta1, but not alpha2beta1, suppresses malignant conversion. Cancer Res 61 (2001) 5248-5254
10. Mercurio A.M., Rabinovitz I., and Shaw L.M. The alpha 6 beta 4 integrin and epithelial cell migration. Curr Opin Cell Biol 13 (2001) 541-545
11. Saintier D., Burde M.A., Rey J.M., Maudelonde T., de Vernejoul M.C., and Cohen-Solal M.D. 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts. J Cell Physiol 198 (2004) 269-276
12. Hoffmann T.K., Bojar H., Eckel J., van Lierop A., Balz V., Friebe-Hoffmann U., et al. Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck. Anticancer Drugs 13 (2002) 521-531
13. Kim M.J., Lee J.H., Kim Y.K., Myoung H., and Yun P.Y. The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines. Cancer Lett 245 (2007) 284-292
14. Shapira A., Virolainen E., Jameson J.J., Ossakow S.J., and Carey T.E. Growth inhibition of laryngeal UM-SCC cell lines by tamoxifen. Comparison with effects on the MCF-7 breast cancer cell line. Arch Otolaryngol Head Neck Surg 112 (1986) 1151-1158
15. Tavassoli M., Soltaninia J., Rudnicka J., Mashanyare D., Johnson N., and Gaken J. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1. Carcinogenesis 23 (2002) 1569-1575
16. Nelson K, Helmstaedter V, Lage H. The influence of tamoxifen on growth behavior and cell-cell adhesion in OSCC in vitro. Oral Oncol, in press, doi:10.1016/j.oraloncology.2006.09.005.
17. Nelson E.M., Tewey K.M., and Liu L.F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 40-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci 81 (1984) 1361-1365
18. Wichert A., Stege A., Midorikawa Y., Holm P.S., and Lage H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene 23 (2004) 945-955
19. Lage H. Molecular analysis of therapy resistance in gastric cancer. Digest Dis 21 (2003) 326-338
20. Murata T., Narita K., Honda K., and Higuchi T. Changes of receptor mRNAs for oxytocin and estrogen during the estrous cycle in rat uterus. J Vet Med Sci 65 (2003) 707-712
21. Prange-Kiel J., and Rune G.M. Direct and indirect effects of estrogen on rat hippocampus. Neuroscience 138 (2006) 765-772
22. Osborne C.K., Wakeling A., and Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90S1 (2004) S2-S6
23. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19 (2005) 833-842
24. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
25. Papadimitrakopoulou V.A., Brown E.N., Liu D.D., El-Naggar A.K., Jack Lee J., Hong W.K., et al. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 239 (2006) 136-143
26. Wang M.M., Traystman R.J., Hurn P.D., and Liu T. Non-classical regulation of estrogen receptor-alpha by ICI182,780. J Steroid Biochem Mol Biol 92 (2004) 51-62
27. Dhandapani K.M., Wade F.M., Mahesh V.B., and Brann D.W. Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways. Endocrinology 146 (2005) 2749-2759
28. Naim R., Chang R.C., Schultz J., and Hormann K. Chemopreventive alteration of the cell-cell adhesion in head and neck squamous cell cancer. Oncol Rep 16 (2006) 273-277
29. Evans R.D., Jones J., Taylor C., and Watt F.M. Sequence variation in the I-like domain of the beta1 integrin subunit in human oral squamous cell carcinomas. Cancer Lett 213 (2004) 189-194
30. Givant-Horwitz V., Davidson B., and Reich R. Laminin-induced signaling in tumor cells. Cancer Lett 223 (2005) 1-10
31. Kim W.H., Lee B.L., Kim D.K., and Kleinman H.K. Laminin-1-adherent cancer cells show increased proliferation and decreased apoptosis in vivo. Anticancer Res 19 (1999) 3067-3071
32. Patarroyo M., Tryggvason K., and Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 12 (2002) 197-207
33. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G Protein in human breast cancer cells. Endocrinologyl 146 (2005) 624-632
34. Brockbank E.C., Bridges J., Marshall C.J., and Sahai E. Integrin beta1 is required for the invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. Br J Cancer 92 (2005) 102-112
35. Warner M., and Gustafsson J.A. Nongenomic effects of estrogen: why all the uncertainty?. Steroids 71 (2006) 91-95
36. Ginsberg M.H., Partridge A., and Shattil S.J. Integrin regulation. Curr Opin Cell Biol 17 (2005) 509-516
37. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., and Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307 (2005) 1625-1630
38. Nemenoff R.A., and Winn R.A. Role of nuclear receptors in lung tumourigenesis. Eur J Cancer 41 (2005) 2561-2568